The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,472,694 in first-year total cost, median $736,347.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-C (F1)]2
Most frequent institutions
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
- UNIVERSITY OF COLORADO DENVER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease1UG3HL152323-01 | D'ARMIENTO, JEANINE MSTRANGE, CHARLTON B | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $740,205 | ZHL1 |
| 2020 | Preclinical Pulmonary Fibrosis, an opportune rare disease cohort1UG3HL151865-01 | SCHWARTZ, DAVID ALBERT | UNIVERSITY OF COLORADO DENVER, CO | $732,489 | ZHL1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.